Market analysis, regulatory registration, marketing and distribution of medical products across Kazakhstan, Central Asia and the CIS region.
Founded in 2009, JetCross provides integrated services in the pharmaceutical market in Kazakhstan, Central Asia, Russia, Ukraine, Mongolia and South Caucasus.
We help clients navigate the complexities of registration and achieve approval in record time — 12 months versus the industry standard of 18–36.
Dedicated professional team with long-term relationships with experts and government officials.
Using deep process knowledge to conduct preliminary consultations and submit a perfect dossier.
Continuously monitoring document progress within regulatory bodies to avoid all bottlenecks.
From initial market analysis through to distribution, we manage every step of your market entry.
Exceptional understanding of market dynamics, competitive landscape, key players and latest trends in the CIS pharmaceutical space.
Decades of collective marketing and market research expertise in emerging markets pharma, all conducted in-house for data coherence.
Superior regulatory process understanding, with tens of registrations successfully completed or underway across multiple jurisdictions.
Deep-rooted relationships and decades of experience dealing with key opinion leaders and decision makers across different regions.
Expert understanding of the distributor landscape — each distributor's strengths and weaknesses — along with great existing relationships.
Complete product lifecycle support including our proprietary Sorion platform and partnerships across the medical devices and food supplements categories.
Every pharmaceutical registration in Kazakhstan follows these stages. We manage and accelerate each one.
JetCross conducts a preliminary review of your dossier and product data. We identify any gaps before submission, ensuring a clean first-round filing that avoids costly delays.
We guide pharmaceutical companies through every government listing and price approval process required to access the full breadth of the Kazakhstan market — from state procurement to outpatient reimbursement.
Electronic Register of Inpatients — Price Approval
Approval of the price per dosage of medicines in the Electronic Register of Inpatients.
Single Distributor List — GVFMC Inclusion
Inclusion of a medicinal product in the list of medicines purchased from the Single Distributor within the guaranteed volume of free medical care.
Reference Pricing — Price Registration
Registration of prices within the framework of the reference pricing procedure in the Republic of Kazakhstan.
Free & Preferential Outpatient Provision List
Inclusion in the list of medicines and medical devices for free and/or preferential outpatient provision to certain categories of citizens with certain diseases.
Orphan Disease List — Inclusion
Inclusion in the list of orphan diseases and medicines designated for their treatment in Kazakhstan.
Regulatory approval alone is not enough. To reach patients at scale in Kazakhstan, your product must be included in the right government lists — from state procurement to outpatient benefits. Without these listings, sales volume is severely limited. JetCross navigates all five pathways on your behalf.
We have deep experience working with rare disease products, supporting both the orphan designation process and subsequent inclusion in Kazakhstan's national orphan disease treatment list — a critical step for patient access and reimbursement.
Select your product type and target markets. We'll show you realistic timelines and how JetCross compresses them.
Estimates based on typical engagements. Actual timelines vary by product complexity and regulatory changes.
A selection of companies we have partnered with
We provide professional, end-to-end business support in the markets of medicines, medical devices and diagnostics across six countries of the region — with a precise focus on the key priorities of each client.
Comprehensive intelligence gathering, regulatory landscape analysis and strategic government relations consulting tailored to each country's unique political and regulatory environment.
Evidence-based analytical support to facilitate productive dialogue and alignment between pharmaceutical companies, regulatory authorities and patient communities across the region.
Direct engagement with government ministries, health authorities, professional associations, patient advocacy groups and other key stakeholders to advance your business objectives across all six markets.
Our regional coverage is built on 15+ years of on-the-ground relationships with government officials, healthcare decision-makers and distribution networks across all six countries.
Click any country to explore market size, growth outlook and JetCross service coverage.
JetCross is the exclusive distributor of the AG-170 photocatalyst antibacterial lighting tube in Kazakhstan and Central Asia — bringing a clinically-tested air and surface disinfection technology from Shaanxi Aigu Medical Co., Ltd. (China) to healthcare facilities, hospitality, education and food service businesses across the region.
Unlike traditional UV-C germicidal lamps that require empty rooms, the AG-170 uses a flicker-free, blue-light-free safe light source combined with a patented titanium dioxide / silver-ion coating. The light activates the coating through a photocatalytic reaction, generating reactive oxygen species that continuously suppress and destroy airborne and surface bacteria — while people remain in the room.
Independent test results for the 60 cm AG-170 lamp:
Also demonstrates measurable inhibitory and germicidal effects against Staphylococcus aureus (≥60% inhibition, 8h) and Candida albicans (≥54% inhibition, 8h). Blue-light hazard tested at RG0 (lowest risk group) — safe for prolonged human exposure.
Independent verification was conducted in an active raw-material loading room (~25 m³) at a major pharmaceutical company, using ISO Class 8 (100,000-grade) cleanroom testing methodology with 8 AG-170 (60cm) units installed and 2 sampling points per metric.
Result: ≥73% reduction in settled bacteria and ≥80% reduction in airborne bacteria after 8 hours of continuous operation.
No UV radiation, no blue light, no flicker. Operates continuously in occupied spaces — overcoming the core limitation of traditional UV-C germicidal lamps.
The photocatalyst coating is not consumed during operation — antibacterial performance remains constant across the full 15,000-hour rated lifetime.
Demonstrated activity against dozens of common bacteria, moulds and viruses, plus decomposition of airborne odour compounds — combining disinfection, mould prevention and air purification.
Installs exactly like a standard fluorescent tube — same fitting, same wiring, no electrical modification required. Direct replacement or supplementary installation.
Produced by Shaanxi Aigu Medical Co., Ltd. — holder of a Disinfection Product Production Enterprise Hygiene Licence and the first company in China to develop and mass-produce this lamp category.
Available in different shapes and power ratings to suit diverse facility requirements, and can be deployed alongside existing UV systems to extend coverage.
Suitable for non-sterile environments where continuous air and surface hygiene matters:
Recommended density: 2 units per 10 m² for residential use; 4 units per 10 m² for public/commercial spaces. Custom designs available for large venues (conference centres, airports, stations).
Manufactured by Shaanxi Aigu Medical Co., Ltd. (Baoji, Shaanxi Province, China) under execution standard Q/SXAGYL 001-2025. The manufacturer holds a Disinfection Product Production Enterprise Hygiene Licence and operates a dedicated production workshop with full quality management systems. As JetCross brings this product to Kazakhstan and the EAEU, our regulatory affairs team manages the full import compliance pathway — EAEU technical regulation conformity (TR EAEU 004/2011, TR EAEU 020/2011), customs clearance, and Kazakh/Russian-language labelling — leveraging the same expertise JetCross applies to pharmaceutical and medical device registration.
JetCross is the authorised distributor of NEOIAL HC in Kazakhstan — a Class III CE-certified sterile hydrogel for intra-articular injection manufactured by Sifra S.r.l., Pistoia, Italy. The first intra-articular product combining hyaluronic acid with recombinant silk-worm collagen (NEOSILK®).
Unlike bovine or porcine collagen, NEOSILK® has 99.9% structural similarity to human collagen — hypoallergenic and non-immunogenic.
Contains dual molecular weight HA (LW 1.8000% + MW 0.2000%) for optimised viscosity, lubrication and shock absorption.
The collagen component directly stimulates chondrocyte proliferation — more durable results than HA alone, addressing cartilage matrix not just symptoms.
CE Class III — certified by Notified Body (CE 0477). Single-use pre-filled syringe. Manufactured by Sifra S.r.l. & INNATE S.r.l., Pistoia, Italy.
For use by qualified medical personnel only under strict aseptic conditions.
| Presentation | HA Concentration | HA Content | Injection Protocol |
|---|---|---|---|
| 2 ml | 2.0% | 40 mg | 3 weekly injections; then 1–several maintenance injections at physician's discretion |
| 4 ml | 1.5% | 60 mg | 1–2 injections per cycle; then maintenance injections at physician's discretion |
| 4 ml | 2.0% | 80 mg | 1–2 injections per cycle; then maintenance injections at physician's discretion |
Water for injections q.s. to 100 · Sodium hyaluronate LW 1.8000% · Sodium hyaluronate MW 0.2000% · Recombinant collagen 0.0005% · Carboxymethylcellulose sodium 1.8000% · Sodium chloride 0.8000% · Sodium phosphate dibasic dodecahydrate 0.1500% · Sodium phosphate monobasic dihydrate 0.0300%
For use by qualified medical personnel only. Contraindicated in hypersensitivity to any ingredient. Do not inject into infected joints. Not for use in pregnancy/breastfeeding. Side effects are mild and transient. Store at 2–25°C. Do not freeze.
SIFRA S.r.l.
Via dello Stadio 20 · 51100 Pistoia, Italy
Tel: +39 0573 1716561
E-mail: info@sifra-srl.it
www.sifra-srl.it
Manufacturing site: INNATE S.r.l., Via dello Stadio 20, 51100 Pistoia, Italy
JetCross LLP (ТОО «Jetcross»)
Republic of Kazakhstan, 050000, Almaty
Timiryazeva str. 42, pavilion № 15/1, office 1
Tel: +77085910281
E-mail: bibigul.begimbetova@gmail.com
Answer 4 quick questions and we'll tell you exactly which JetCross service fits your situation.
We are a young and ambitious company that brings deep market intelligence and authentic relationships to every partnership.
Extensive industry experience allows us to develop a clear understanding of market trends, industry dynamics, and future drivers.
All consulting work is carried out in-house, ensuring data coherence and the highest quality analysis — no outsourcing.
We consult with an extensive network of opinion leaders and local market players to receive the latest available data.
Current intelligence on Kazakhstan's pharmaceutical market, EAEU regulations and Central Asia market entry strategy.
The JetCross client portal gives you real-time visibility into your dossier progress, upcoming regulatory deadlines and key contacts — no more chasing updates by email.
Reach out to learn how JetCross can accelerate your pharmaceutical product registration and distribution across the CIS.
42, Timiryazeva str, building 15/1, office 1
Almaty, Kazakhstan 050057